Display Post Content

Sydney Neuroimaging Analysis Centre (SNAC) secures A$2.36 million Australian Government CRC-P Grant to transform Clinical Neuroimaging with AI.

 

Deep_learning.png

 

·      SNAC is the lead participant in a successful CRC-P grant application: AI: new smarts for the medical imaging industry

·      The CRC-P grant provides A$2.36 million funding, with additional matched cash and in-kind participant funding.

·      Together with national imaging provider I-MED Radiology Network (I-MED) and the University of Sydney’s Brain and Mind Centre, SNAC will develop, implement and commercialise clinically meaningful AI algorithms in the clinical and clinical trials neuroimaging space.

 

Sydney Neuroimaging Analysis Centre (SNAC) is pleased to announce its recent success in securing support for its Artificial Intelligence in Neuroimaging project through the Australian Government’s Cooperative Research Centres (CRC) Programme.  As the lead participant, SNAC has been awarded a A$2.36 million grant, with matched cash and in-kind funding from the project participants, including SNAC, I-MED and the University of Sydney’s Brain and Mind Centre.

 

The Cooperative Research Centres (CRC) Programme is administered by AusIndustry, a division within the Department of Industry, Innovation and Science. The CRC Programme is a competitive, merit based grant programme that supports industry-led and outcome-focused collaborative research partnerships between industry, researchers and the community.

 

Dr Tim Wang PhD, Director of Operations for SNAC, said “The provision of CRC-P funding will significantly accelerate the expansion of SNAC’s neuro-imaging biomarker portfolio, enhance clinical trials of emerging therapies for neurological disorders such as multiple sclerosis and, through our partnership with I-MED, transform diagnostic neuroimaging”

 

“Partnership with the Computational Neuroscience Team at the University of Sydney’s Brain and Mind Centre, led by neurologist Professor Michael Barnett and AI expert Professor Dacheng Tao, is a pivotal strength of the project”.

 

SNAC specialises in the provision of regulatory-compliant neuroimaging analysis to the pharmaceutical industry and in particular the development of novel neuroimaging biomarkers and their implementation in Phase 2-4 clinical trials.  SNAC also works closely with academics in imaging science and clinical medicine to further research into neurological disease.

 

For more information please contact:   

 

Dr Tim Wang, Director of Operations

Email: tim@snac.com.au

Web: snac.com.au

 

SNAC values open sharing of scientific knowledge. We regularly publish the findings of our research in high impact journals, contribute to international academic meetings such as MICCAI, ISMRM, and ECTRIMS. We have deep collaborations with academics at the University of Sydney’s Brain and Mind Centre; and with other imaging centres across the globe.

Journal Papers

 


Ting Shen, Yuyi You, Sukanya Arunachalam,  Ariadna Fontes, Sidong Liu, Vivek Gupta,  John Parratt,  Chenyu     Wang, Michael Barnett, Joshua Barton, Nitin Chitranshi, Ling Zhu, Clare L. Fraser,  Stuart L. Graham, Alexander Klistorner and  Con Yiannikas
“Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.”Ophthalmology, 2018; 1–9.

Alexander Klistorner, Chenyu Wang, Con Yiannikas, John Parratt, Joshua Barton, Yuyi You, Stuart L. Graham, and Michael H. Barnett. “Diffusivity in the Core of Chronic Multiple Sclerosis Lesions.”PLoS ONE13, no. 4 (2018): 1–20.

Alexander Klistorner, Chenyu Wang, Con Yiannikas, John Parratt, Michael Dwyer, Joshua Barton, Stuart L. Graham, Yuyi You, Sidong Liu, and Michael H. Barnett. “Evidence of Progressive Tissue Loss in the Core of Chronic MS Lesions: A Longitudinal DTI Study.”NeuroImage: Clinical17, no. October 2017 (2018): 1028–35.  

Chenyu Wang, Alexander Klistorner, Linda Ly, and Michael H. Barnett. “White Matter Tract-Specific Quantitative Analysis in Multiple Sclerosis: Comparison of Optic Radiation Reconstruction Techniques.”PLoS ONE13, no. 1 (2018): 1–19. 

Grace Lu, Heidi N. Beadnall, Joshua Barton, Todd A. Hardy, Chenyu Wang, and Michael H. Barnett. “The Evolution of ‘No Evidence of Disease Activity’ in Multiple Sclerosis.”Multiple Sclerosis and Related Disorders20, no. October 2017 (2018): 231–38. 

Stephen W. Reddel, Michael H. Barnett, Sean Riminton, Tej Dugal, Katherine Buzzard, Chenu Wang, Fiona Fitzgerald, Heidi N. Beadnall, Diane Erickson, David Gahan, Faniel Wang, Toby Ackland and Richard Thompson. “Successful Implementation of an Automated Electronic Support System for Patient Safety Monitoring: The Alemtuzumab in Multiple Sclerosis Safety Systems (AMS3) Study.”Multiple Sclerosis Journal(2018), 135245851878367.

Alexander Klistorner, Elizabeth C. Graham, Con Yiannikas, Michael Barnett, John Parratt, Ray Garrick, Chenyu Wang, Yuyi You, and Stuart L. Graham. “Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations.” European journal of neurology24, no. 11 (2017): 1392-1398.

Christine Egger, Roland Opfer, Chenyu Wang, Timo Kepp, Maria Pia Sormani, Lothar Spies, Michael H. Barnett, and Sven Schippling. “MRI FLAIR Lesion Segmentation in Multiple Sclerosis: Does Automated Segmentation Hold up with Manual Annotation?”NeuroImage: Clinical13 (2017): 264–70. 

Joshua Barton, Todd A. Hardy, Sean Riminton, Stephen W. Reddel, Yael Barnett, Alasdair Coles, and Michael H. Barnett. “Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.” Neurology 88, no. 10 (2017): 1004-1006.

Nicola De Stefano, Diego G. Silva, and Michael H. Barnett. “Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.”CNS Drugs31, no. 4 (2017): 289–305. 

Swee T. Aw, Luke Chen, Michael J. Todd, Michael H. Barnett, and G. Michael Halmagyi. “Vestibulo-Ocular Reflex Deficits with Medial Longitudinal Fasciculus Lesions.”Journal of Neurology264, no. 10 (2017): 2119–29. 

Alexander Klistorner, Chenyu Wang, Con Yiannikas, Stuart L. Graham, John Parratt, and Michael H. Barnett. “Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study.”PLoS ONE11, no. 2 (2016): 1–11. 

Alexander Klistorner, Chenyu Wang, Vera Fofanova, Michael H. Barnett, Con Yiannikas, John Parratt, Yuyi You, and Stuart L. Graham. “Diffusivity in Multiple Sclerosis Lesions: At the Cutting Edge?”NeuroImage: Clinical12 (2016): 219–26. 

Chenyu Wang, Heidi N. Beadnall, Sean. N. Hatton, Giovanni. Bader, Davorka. Tomic, Diego. G. Silva, and Michael H. Barnett. “Automated Brain Volumetrics in Multiple Sclerosis: A Step Closer to Clinical Application.”Journal of Neurology, Neurosurgery and Psychiatry87, no. 7 (2016): 754–57. 

Robert Zivadinov, Dejan Jakimovski, Sirin Gandhi, Rahil Ahmed, Michael G. Dwyer, Dana Horakova, Bianca Weinstock-Guttman, Ralph R.H. Benedict, Manuela Vaneckova, Michael Barnett and Niels Bergsland. “Clinical Relevance of Brain Atrophy Assessment in Multiple Sclerosis. Implications for Its Use in a Clinical Routine.”Expert Review of Neurotherapeutics16, no. 7 (2016): 777–93. 

Saurabh Jain, Annemie Ribbens, Diana M. Sima, Melissa Cambron, Jacques De Keyser, Chenyu Wang, Michael H. Barnett, Sabine Van Huffel, Frederik Maes, and Dirk Smeets. “Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework.”Frontiers in Neuroscience10, no. DEC (2016): 1–11. 

Sudarshini Ramanathan, Kristina Prelog, Elizabeth H. Barnes, Esther M. Tantsis, Stephen W. Reddel, Andrew P.D. Henderson, Steve Vucic, Mark P. Gorman, Leslie A. Benson, Gulay Alper, Catherine J. Riney, Michael H. Barnett, John D.E. Parratt, Todd A. Hardy, Richard J. Leventer, Vera Merheb, Margherita Nosadimi, Victor S.C. Fung, Fabienne Brillot and Russell C. Dale . “Radiological Differentiation of Optic Neuritis with Myelin Oligodendrocyte Glycoprotein Antibodies, Aquaporin-4 Antibodies, and Multiple Sclerosis.”Multiple Sclerosis22, no. 4 (2016): 470–82. 

Todd A. Hardy, Chenyu Wang, Heidi N. Beadnall, Jim Lagopoulos, Yael Barnett, Alexander Klistorner, and Michael H. Barnett. “Wallerian Degeneration in the Corticospinal Tract Following Tumefactive Demyelination: Conventional and Advanced Magnetic Resonance Imaging.”Canadian Journal of Neurological Sciences43, no. 5 (2016): 726–27. 

Todd A. Hardy, Stephen W. Reddel, Michael H. Barnett, Jacqueline Palace, Claudia F. Lucchinetti, and Brian G. Weinshenker. “Atypical Inflammatory Demyelinating Syndromes of the CNS.”The Lancet Neurology15, no. 9 (2016): 967–81. 

Alexander Klistorner, Nikitha Vootakuru, Chenyu Wang, Con Yiannikas, Stuart L. Graham, John Parratt, Raymond Garrick, Netta Levin, Lynette Masters, Jim Lagopoulos and Michael H. Barnett. “Decoding Diffusivity in Multiple Sclerosis: Analysis of Optic Radiation Lesional and Non-Lesional White Matter.”PLoS ONE10, no. 3 (2015): 1–24. 

Chenyu Wang, David Paling, Luke Chen, Sean N. Hatton, Jim Lagopoulos, Swee T. Aw, Matthew C. Kiernan, and Michael H. Barnett. “Axonal Conduction in Multiple Sclerosis: A Combined Magnetic Resonance Imaging and Electrophysiological Study of the Medial Longitudinal Fasciculus.”Multiple Sclerosis21, no. 7 (2015): 905–15. 

Laura Vuillier, Daniel F. Hermens, Kate Chitty, Chenyu Wang, Manreena Kaur, Philip B. Ward, Rachael Degabriele, Ian B. Hickie, and Jim Lagopoulos. “Emotional Processing, P50 Sensory Gating, and Social Functioning in Bipolar Disorder.”Clinical EEG and Neuroscience46, no. 2 (2015): 81–87. 

Alexander Klistorner, Prima Sriram, Nikitha Vootakuru, Chenyu Wang, Michael H. Barnett, Raymond Garrick, John Parratt, Netta Levin, Noa Raz, Anneke Van der Walt, Lynette Masters, Stuart Graham and Con Yiannikas. “Axonal Loss of Retinal Neurons in Multiple Sclerosis Associated with Optic Radiation Lesions.”Neurology82, no. 24 (2014): 2165–72. 

Yael Barnett, Ian J Sutton, Mahtab Ghadiri, Lynette Masters, Robert Zivadinov, and Michael H. Barnett. “Conventional and Advanced Imaging in Neuromyelitis Optica.”American Journal of Neuroradiology35, no. 8 (2014): 1458–66.

Daniah Alshowaeir, Con Yiannikas, Raymond Garrick, John Parratt, Michael H. Barnett, Stuart L. Graham, and Alexander Klistorner. “Latency of Multifocal Visual Evoked Potentials in Nonoptic Neuritis Eyes of Multiple Sclerosis Patients Associated with Optic Radiation Lesions.”Investigative Ophthalmology and Visual Science55, no. 6 (2014): 3758–64.

Megha Kaushik, Stuart L. Graham, Chenyu Wang, and Alexander Klistorner. “A Topographical Relationship between Visual Field Defects and Optic Radiation Changes in Glaucoma.”Investigative Ophthalmology and Visual Science55, no. 9 (2014): 5770–75. 

Prema Sriram, Chenyu Wang, Con Yiannikas, Raymond Garrick, Michael H. Barnett, John Parratt, Stuart L. Graham, Hemamalini Arvind, and Alexander Klistorner. “Relationship between Optical Coherence Tomography and Electrophysiology of the Visual Pathway in Non-Optic Neuritis Eyes of Multiple Sclerosis Patients.”PLoS ONE9, no. 8 (2014): 1–11. 

Megha Kaushik, Chenyu Wang, Michael H. Barnett, Raymond Garrick, John Parratt, Stuart L. Graham, Prema Sriram, Con Yiannikas, and Alexandr Klistorner. “Inner Nuclear Layer Thickening Is Inversley Proportional to Retinal Ganglion Cell Loss in Optic Neuritis.”PLoS ONE8, no. 10 (2013): 1–9. 

Minagar, Alireza, Michael H. Barnett, Ralph H.B. Benedict, Daniel Pelletier, Istvan Pirko, Mohamad Ali Sahraian, Elliott Frohman, and Robert Zivadinov. “The Thalamus and Multiple Sclerosis: Modern Views on Pathologic, Imaging, and Clinical Aspects.”Neurology80, no. 2 (2013): 210–19.

Prema Sriram, Stuart L. Graham, Chenyu Wang, Con Yiannikas, Raymond Garrick, and Alexander Klistorner. “Transsynaptic Retinal Degeneration in Optic Neuropathies: Optical Coherence Tomography Study.”Investigative Ophthalmology and Visual Science53, no. 3 (2012): 1271–75.

 

 

Conference papers/abstracts

 

2018

E. Devenney, T. Wang, H. Beadnall, L. Ly, C. Dawes, S. Liu, M. Barnett, Understanding Memory Impairment in Multiple Sclerosis - contributions of macro and micro-structural alterations in the thalamus and hippocampus, ECTRIMS 2018, Berlin, 10-12 October 2018

C. Wang, A. Klistorner, J. Barton, H. Beadnall, L. Ly, S. Liu, J. Garber, S. Reddel, M. Barnett, Alteration of visual cortical microstructure is associated with pathology along the optic radiation in patient with MS: An asymmetry analysis of posterior visual pathway, ECTRIMS 2018, Berlin, 10-12 October 2018

A. Klistorner, C. Wang, S. Liu, L. Graham, M. Barnett, Diffusivity data suggests progressive lesion-independent demyelination in NAWM of MS patients: a 5 year study, ECTRIMS 2018, Berlin, 10-12 October 2018

S. Liu, A. Klistorner, C. Wang, Y. Gao, B. Gilchrist, Y. You, Y. Song, J. Yao, W. Cai, M. Barnett, “Personalized Lesion Profiling in Multiple Sclerosis", Joint Annual Meeting of ISMRM-ESMRMB, Paris, France (2018).

B. Gilchrist, S. Liu, C. Wang, O. Pasternak, Y. You, A. Klistorner, “Free Water Elimination Improves Tractography through Multiple Sclerosis Lesions", Joint Annual Meeting of ISMRM- ESMRMB , Paris, France (2018)

Z. Tang, C. Wang, P. Hoang, S. Liu, W. Cai, D, D. Soligo, R. Oliver, M. Barnett, C. Formusek, 2018. Automatic Segmentation of Thigh Muscle in Longitudinal 3D T1-weighted Magnetic Resonance (MR) Images. In MICCAI Workshop on Data-driven Treatment Response Assessment (2018). 

2017

A. Klistorner, C. Wang, M. Barnett, Centrifugal pattern of progressive water diffusion increase in chronic MS lesions, 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

M.H. Barnett, D. Silva, C. Wang, N. De Stefano, M. Battaglini, M.P. Sormani, R. Meinert, D. Tomic, D. ArnoldLong­term Disease Outcomes in Multiple Sclerosis Patients Categorised by Baseline Brain Volume and with No Disease Activity over 2 Years , 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

J Garber, C Wang, H Beadnall, T Hardy, J M Capponi, J Howells, M Kiernan, MH Barnett, Structure and function of the corticospinal tract and motor cortex in multiple sclerosis ,7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

C. Wang, J. Barton, A. Klistorner, L. Ly, H.N. Beadnall, S. Reddel, M.C. Kiernan, M.H. Barnett Improving the accuracy of brain tissue loss assessment in patients with multiple sclerosis: a role for diffusion imaging?, 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

H.N. Beadnall, C. Wang, J.M. Matamala, T.A. Hardy, J. Howells, C. Dawel, J. Garber, J. Barton, S. Reddel, M.C. Kiernan, M.H. Barnett, Multiple sclerosis: structure-function correlations in the cerebral cortex,7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

H. Beadnall, T. Billiet, D. Horakova, D.P. Ramasamy, L. Ly, A. Ribbens, M.G. Dwyer, T. Uher, C. Wang, N. Bergsland, E. Havrdova, E. Carl, W. Van Hecke, M. Vaneckova, R. Zivadinov, M.H. Barnett, The effect of quantitative magnetic resonance imaging (QMRI) on no evidence of disease activity (NEDA) status in multiple sclerosis clinical practice: A multicentre retrospective longitudinal study, 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017

C. Wang, J. Barton, A. Klistorner, L. Ly, H.N. Beadnall, S. Reddel, M.C. Kiernan, M.H. Barnett, Conduction velocity in demyelinated cerebral white matter: a structure-function correlation study in optic radiation, 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

A. Klistorner, C. Wang, C. Yiannikas, J. Parratt, M. Barnett, Accelerated loss of chronically demyelinated axons in relapsing-remitting multiple sclerosis, 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

M. Dwyer, N. Bergsland1, D. Horakova, M. Vaneckova, T. Uher, E. Havrdova1, M. Barnett, H. Beadnall, C. Wang, T. Billiet, W.V. Hecke, A. Ribbens, R. Zivadinov, Lateral ventricular atrophy measurements agree better than whole brain measures across centers and measurement techniques" 7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

Beadnall HN, Wang C, Van Hecke W, Ribbens A, Barnett MH. Comparing magnetic resonance imaging brain atrophy measurement techniques in multiple sclerosis clinical practice: Longitudinal assessment. Australian and New Zealand Association of Neurologists (ANZAN) Annual Scientific Meeting 2017 (Platform presentation). Gold Coast, Australia. 11 May 2017.

Grace Lu, Heidi Beadnall, Chenyu Wang, Todd Hardy, Joshua Barton, Michael Barnett. The prognostic utility of No Evidence of Disease Activity (NEDA) Australian and New Zealand Association of Neurologists (ANZAN) Annual Scientific Meeting 2017 (Platform presentation). Gold Coast, Australia. 11 May 2017.

D. Arnold , M. Barnett, et. al,  Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study, 69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017. 

A. Traboulsee, M. Barnett, G. Comi , C. LaGanke, D. Pelletier, A. Rovira , S. Schippling , D. Margolin , K. Thangavelu, K. Nakamura , D. Arnold , o. and CAMMS03409 Investigators. Alemtuzumab Durably Slows Brain Volume Loss Over 6 Years in the Absence of Continuous Treatment in Patients With Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II), 69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017 

D. Pelletier, M. Barnett, et. al Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up, 69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017. 

A. Boyko, M. Barnett, et. al Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up, 69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017.  

S. Schippling, A. Traboulsee, M. Barnett, et. al Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II ,  69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017.

Beadnall HN, Wang C, Van Hecke W, Ribbens A, Barnett MH. Longitudinal brain atrophy measurement techniques in clinical multiple sclerosis practice using magnetic resonance imaging. 69th American Academy of Neurology (AAN) Annual Meeting (P4.374). Boston, United States of America. 26 April 2017 

Ribbens A, Billiet T, Beadnall HN, Vaneckova M, Weinstock-Guttman B, Ly L, Wang C, Carl E, Claes L, Dwyer M, Krasensky J, Uher T, Horakova D, Van Hecke W, Barnett M, Zivadinov R. Assessment of Brain Atrophy in Multiple Sclerosis Patients in Clinical Routine: A Multi-Center Comparison Study of Radiological and Quantitative Reports.69th American Academy of Neurology (AAN) Annual Meeting (P4.373). Boston, United States of America. 26 April 2017 

Ribbens A, Billiet T, Beadnall HN, Vaneckova M, Weinstock-Guttman B, Ly L, Wang C, Ramasamy D, Houbrechts R, Bergsland N, Seidl Z, Uher T, Van Hecke W, Horakova D, Zivadinov R, Barnett M. Association of Quantitative MRI to Radiological Reporting for the Evaluation of Lesion Burden Status in Multiple Sclerosis: A Multi-Center Study. 69thAmerican Academy of Neurology (AAN) Annual Meeting (P4.358). Boston, United States of America. 26 April 2017.

D. Pelletier, B, Barnett et. al. Alemtuzumab reduced MRI lesions and slowed brain volume loss in CARE-MS II patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study),7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017. 

A. Rovira, B. Barnett et. al. Alemtuzumab decreased MRI disease activity and slowed brain volume loss over 5 years after switching from SC IFNB-1a: follow-up of CARE-MS I (TOPAZ study),7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017. 

D. Pelletier, Patients with active RRMS experience durable reductions in MRI disease activity and slowing of brain volume loss with alemtuzumab: 7-year follow-up of CARE-MS II patients (TOPAZ study),7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

M.Min, M. Barnett et. al. Silent lesions on MRI - shifting goal post for treatment decisions in MS,7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

D.L. Arnold, M. Barnett, et. al. Durable reduction in MRI disease activity and slowing of brain volume loss with alemtuzumab in patients with active RRMS: 7-year follow-up of CARE-MS I patients (TOPAZ study),7th Joint ECTRIMS-ACTRIMS meeting, Paris, 25 - 28 October 2017.

Ruth Oliver, Heidi Beadnall, Chenyu Wang, Matthew Kiernan, Todd Hardy, Michael Barnett "Arterial spin labelling measurements of cortical perfusion in multiple sclerosis show widespread reduced cortical metabolism" ISMRM 25th Annual Meeting, electronic poster #1885, Honolulu, USA, 22-27 April 2017.

2016

C. Wang, A. Klistorner, L. Ly, V. Fofanova, M.H. Barnett, “Optic Radiation Reconstruction in Patients with Multiple Sclerosis: Template Based Approach vs. Individual Tractography Based Method”, ISMRM Workshop on Breaking the Barriers of Diffusion MRI, Lisbon, Portugal, 2016

C. Wang, L. Ly, A. Klistorner, H. Beadnall, J. Barton, R. Oliver, M.H. Barnett, "Quantifying Lesion Progression in Multiple Sclerosis: a novel Magnetic Resonance Imaging pipeline" 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016 

C. Egger, R. Opfer, C. Wang, T. Kepp, L. Spies, M.P. Sormani, M. Barnett, S. Schippling “Automated segmentation of FLAIR lesion volume and number: Validation and comparison to manual inter-rater variability” 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016.

A. Klistorner, V. Fofanova, C. Wang, M. Barnett, J. Parratt, C. Yiannikas. “Diffusivity in multiple sclerosis lesions: at the cutting edge?” 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016.

Saurabh Jain, Annemie Ribbens, Diana M. Sima, Melissa Cambron, Jacques De Keyser, Chenyu Wang, Michael H Barnett, Sabine Van Huffel, Frederik Maes, Anke Maertens, Dirk Smeets “Longitudinal assessment of brain lesion changes in follow-up MRI scans of patients with Multiple Sclerosis” 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016 

R.A. Oliver, L. Ly, H. Beadnall, C. Wang, T. Hardy, M.H. Barnett “Comparison of cortical perfusion between relapse-remitting multiple sclerosis patients and healthy controls measured using Arterial Spin Labeling MRI” 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016.

R. Zivadinov, F. Schweser, C. Dawes, J. Hagemeier1, L. Ly, C. Wang, N. Bergsland, H. Beadnall, E. Carl, B. Weinstock-Guttman, R.R. Benedict, M. Barnett", A multicentre study of quantitative susceptibility mapping in sub-cortical deep gray matter structures in relapsing multiple sclerosis" 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, London, 14-17 September 2016.

H. N. Beadnall, L. Ly, C. Wang, R Oliver, G Lu, M. H. Barnett. The role of quantitative magnetic resonance imaging (QMRI) in clinical decision making in multiple sclerosis. Australian and New Zealand Association of Neurologists (ANZAN) Annual Scientific Meeting 2016 (Platform presentation – Young Investigator Session). Perth, Australia. 24-27 May 2016.

B. N. Heidi, C. Wang, T. Burke, R. Oliver, S.N. Hatton, J. Barton, L. Ly, S. Vucic, M.H.Barnett, Whole brain volume quantification in multiple sclerosis: ready for translation into clinical practice? American Academy of Neurology 68th Annual Meeting, Poster #209. Vancouver, Canada. 15-21 April 2016.

C. Wang, A. Klistorner, L. Ly, R.A. Oliver, M.H. Barnett, "A New Method to Construct and Validate an Optic Radiation Template using Probabilistic Tractography" ISMRM 24th Annual Meeting, electronic poster #3955, Singapore, 10 May 2016.

R. Oliver, L. Ly, C. Wang, H. Beadnall, Il. B. Galazzo, M. Chappell, X. Golay, E. De Vita, D.Thomas, and M. H. Barnett “Complete partial volume solution for ASL brain perfusion data applied to relapsing-remitting multiple sclerosis patients" ISMRM 24th Annual Meeting, Poster #1976,Singapore, 10 May 2016.

2015

C. Wang, A. Klistorner, R.A. Oliver, L. Ly, M.H. Barnett, "A novel MRI pipeline for assessing multiple sclerosis lesion evolution in the optic radiation" 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. Barcelona, 7 - 10 October 2015 

H.N. Beadnall, C. Wang, R.H. Benedict, C. Dawes, M.H. Barnett, "Tablet-based waiting room cognitive screening in a multiple sclerosis clinic", 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. Barcelona, 7 - 10 October 2015.

A. Klistorner, C. Yiannikas, J. Parratt, C. Wang, Y.T. Liu, S.L. Graham, M.H. Barnett "Evidence of progressive demyelination and neurodegeneration in chronic MS lesions: DTI study", 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress. Barcelona, 7 - 10 October 2015.

Y. You, M. Kaushik. C. Wang, S. Graham, A. Klistorner “Degenerative changes in the optic radiation and the primary visual cortex in glaucoma patients: an MRI study” The 6th World Glaucoma Congress, Poster #122, Hongkong 6-9 June, 2015.

C. Wang, H. N. Beadnall, T. Burke, R. Oliver, S.H. Hatton, J. Barton, L. Ly, S. Vucic M.B. Barnett. . Quantifying brain atrophy: ready for translation to clinical practice? Australian & New Zealand Association of Neurologists (ANZAN) 2015 Conference (Platform Presentation #82). Auckland, New Zeatland. May 12-15, 2015.

C. Wang, H.N. Beadnall, S.N. Hatton, G. Bader, D. Tomic, D.G. Silva, M.H. Barnett, Whole Brain Volume Measurements in Multiple Sclerosis: Cross-Sectional Data Comparison Between Three Methods. American Academy of Neurology 67th Annual Meeting Poster #P6.154. Washington, DC. 18-25 April 2015.

2014

Clarke AJ, Wang C, Beadnall H, Ghadiri M, Chohan G, Masters L, Barnett Y, Hatton SN, Lagopoulos J, Hagemeier J, Zivadinov R, Barnett MH (2014) Biomarkers of neurodegeneration in multiple sclerosis. 7th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress. Taipei, Taiwan. 6-8 November 2014.

Hatton SN, Lagopoulos J, Wang C, Beadnall H, Ghadiri M, Chohan G, Masters L, Barnett Y, Barnett MH (2014) Magnetic Resonance Spectroscopy Measurements In Normal-Appearing White Matter As A Biomarker Of Whole Brain White Matter Integrity In Relapsing Remitting Multiple Sclerosis. 7th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress (Poster #P20). Taipei, Taiwan. 6-8 November 2014

C. Wang, D. Paling, L. Chen, S. N. Hatton, J. Lagopoulos, S. T. Aw, M. C. Kiernan, M. H. Barnett “Medial longitudinal fasciculus: a window on axonal function in multiple sclerosis”, Australian & New Zealand Association of Neurologists (ANZAN) 2014 Conference (Poster #62). Sydney, Australia. May 18-22, 2014.

2013

A. Klistorner, P. Sriram, N. Vootakuru, C. Wang, M. Barnett, R. Garrick, J. Parratt, N. Levin, N. Raz, L. Masters, S. Graham, C. Yiannikas, “Understanding mechanisms of axonal loss in non-optic neuritis eyes of multiple sclerosis patients” 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis & 18th Annual Conference of Rehabilitation in MS. Copenhagen, Denmark. 2~5 October 2013.

M. Kaushik, A. Klistorner, C. Wang, M. Barnett, R. Garrick, J. Parratt, S. Graham, C. Yiannikas “Inner nuclear layer thinning is proportional to the loss of retinal ganglion cells in optic neuritis” 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis & 18th Annual Conference of Rehabilitation in MS. Copenhagen, Denmark. 2~5 October 2013

C. Wang, D Paling, S Aw, MH Barnett, L Chen, S Hatton, J Lagopoulos “Lesion Length Along the Medial Longitudinal Fasciculus Correlates with Neuroaxonal Conduction Delay in Multiple Sclerosis” Multiple Sclerosis as a Whole-Brain Disease, ISMRM scientific workshop, London, England, UK, June 2013.

2012

P. Sriram, N. Saakova, C.Wang, H. Arvind, S. Graham, C. Yianikus, R. Garrick, M. Barnett, J. Parrett, A, Klistorner. “Ganglion cells loss in non-optic neuritis eyes of MS patients” 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France, October 2012.

P. Sriram, N. Saakova, C. Wang, S. Graham, C. Yiannikus, R. Garrick, A. Klistorner “Retinal structure and function in eyes of Multiple Sclerosis patients with no optic neuritis,” 50th International Society for Clinical Electrophysiology of Vision Symposium, Valencia, Spain, June 2012 

 

 

screen-4.png

 

Screen Shot 2018-08-02 at 10.27.42 am.png

 

 

 

The role of Research Scientist-AI inMedical imaging is to develop and implement AI solutions to improve the productivity and enhance reporting accuracy in clinical imaging practice, and contribute to the AI in Neuroimaging collaboration between the University of Sydney, Sydney Neuroimaging Analysis Centre (SNAC) and I-MED Radiology Network (I-MED).

Context of the Role

The recent Interdisciplinary collaboration between the University of Sydney, SNAC and I-MED will deliver a platform for seamless AI integration into clinical radiology workflows; and develop neuroimaging algorithms that will set a benchmark in diagnostic imaging, drive industry automation and productivity and mine hitherto untapped quantitative imaging data to improve health outcomes.  The collaboration is centred on industry-led innovation within the government science and research priority of HEALTH, and aligns with the Medical Technologies and Pharmaceuticals growth sector.

The University of Sydney is Australia’s premier University with an outstanding global reputation for academic and research excellence, and employs over 7600 permanent staff supporting over 60,000 students. The University of Sydney's Brain and Mind Centre was established in 2015 for the research and treatment of critical health issues of the 21st century – disorders of the brain and mind. 

SNAC has been established at the Brain Mind Centre to take advantage of unique research capacity in the field and provide a state of the art commercial facility for the quantitative analysis of MRI to the pharmaceutical and other industries since 2012.  Together with a dedicated MS clinic, MS Clinical Trials Centre, and MRI unit,  SNAC is collocated within the Brain & Mind Centre at the University of Sydney. SNAC offers a unique combination of in-house neuroscience, imaging science, clinical trial, neurology and radiology expertise; and specialise in building novel neuroimaging biomarkers and integrating these into Phase 2-4 clinical trials for the pharmaceutical industry.

I-MED Radiology Network is the largest provider of radiology service in Australia, providing over five million services a year to the Australian community across all states.

Duties and Key Responsibilities

  • Designs, Develops and implements AI solutions for clinical imaging practice to improve the clinical reporting accuracy and productivity.
  • Liaises with project Systems Engineer to implement and deliver the AI solutions to clinicians and clinical research scientists.
  • Contributes to the advancement of AI in medical imaging, including producing publications in top tier journals and conferences. 
  • Plans and Manages the progress of designated AI project, ensures that all deadlines are met. 
  • Provides regular technical and other progress reports relevant to the projects, ensure all progresses are well documented.
  • Provides supports to other members in the team, 
  • Ensures strict confidentiality and security of all databases and related clinical trials information.
  • Provides supervision to junior engineers and research students
  • Undertakes ad-hoc projects and other activities as approved by the supervisor.

 Skills, Knowledge and Experience

  • PhD in computer science/electrical engineering/Applied Math etc, as well as relevant experience in Artificial Intelligence.
  • Demonstrated Excellent experience in computer vision and deep learning.
  • Demonstrated strong hands-on coding skills in C++, Python and other scripting languages to quickly prototype Deep/Machine Learning models on platforms such as TensorFlow/Keras/Pytorch/Theano.
  • Experience with medical imaging analysis is preferred, specifically in classification, segmentation and multimodal analysis.
  • Excellent interpersonal, verbal and written communication skills with sound negotiating and conflict resolution skills and a demonstrated level of tact and discretion in dealing with a variety of matters.
  • Ability to work both independently and as part of a team, taking initiative and exercising sound judgement in resolving matters that may arise as part of normal daily work.
  • Demonstrated experience in planning, analysis and communication skills together with the ability to work according to strict deadlines and manage various demands.
  • Excellent administrative skills, coupled with a general understanding of the project life cycle, project documentation, project standards and methodologies.
  • Previous work experience in the higher education/tertiary sector or at a complex, multi-faceted organisation.

 

SNAC is an equal employment opportunity employer committed to equity, diversity and social inclusion. 

Please forward your application letter and CV to info@snac.com.auWe will be reviewing applications as we receive them however due to the volume of the applications, please be informed that only shortlisted candidates will be contacted after the closing date.

Job Type: Full-time

 

 

 

Here you will find the latest news, tweets, posts and press releases about SNAC and our collaborators. If you like what you see, please be sure to ‘like’ or repost!

Picture1.png

screen-5.png

 

SNAC uses structural and advanced image analysis to further the understanding of neurological disorders, and develop tailored imaging biomarkers for clinical trials of emerging therapeutics. Our quantitative biomarker research has been translated to Phase 2 clinical trials of emerging pro-remyelinating therapies; and composite MRI-electrophysiology studies has yielded new insights into sub-clinical, disease-related injury to brain structure-function networks. The recent incorporation of AI into SNAC’s research pipelines, rapidly accelerate the development of neuroimaging ‘smarts’ for both clinical trials and the diagnostic imaging industry.

 

 screen-1.png

screen-2.png